Lupin Cuts Forecast Despite Etanercept Launch
Firm Sees Trump 'Buy American' Order As Near-Term Opportunity
Executive Summary
Despite plans to launch a biosimilar to Enbrel in August and a generic to ProAir in September, Lupin cut its FY21 EBITDA forecast to 17% from 19-20%, as first-quarter revenues were hit by COVID-19 and a recall of metformin in the US. Meanwhile, it sees the US “Buy American” order for some essential medicines as a near-term opportunity.
You may also be interested in...
Lupin Gives Direction On Pegfilgrastim And Ranibizumab
Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.
Generics Industry Counts Cost Of Stormy Second Quarter
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.
Lupin And Mylan Launch Etanercept in Germany
In partnership with Lupin, Mylan introduces Nepexto (etanercept) to the German market. After adalimumab, Nepexto is Mylan’s second immunology product in Germany.